Log In Get Started
Press Releases April 2, 2026 05:05 PM

2026 Annual General Meeting

Golar LNG Announces Details for 2026 Annual General Meeting on May 19

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
GLNG

Golar LNG Limited has announced that its 2026 Annual General Meeting will be held on May 19, 2026. The company has provided the Notice of Meeting and its Annual Report on Form 20-F online for shareholders and interested parties to review.

2026 Annual General Meeting
GLNG
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • 2026 Annual General Meeting scheduled for May 19, 2026.
  • Notice of Meeting and Annual Report are available on the company's website.
  • The company is compliant with Norwegian Securities Trading Act disclosure requirements.

Further to the press release of March 26, 2026 giving notice that the Golar LNG Limited 2026 Annual General Meeting will be held on May 19, 2026, a copy of the Notice of Annual General Meeting and associated information including the Company’s Annual Report on Form 20-F can be found on our website at https://www.golarlng.com and in the attachments below.

Golar LNG Limited
Hamilton, Bermuda
April 2, 2026

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act


Risks

  • Potential uncertainties related to shareholder decisions at the AGM.
  • Market conditions impacting LNG shipping sector may influence company outlook.
  • Geopolitical or regulatory changes affecting international LNG shipping could impact operations.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026